HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Pituitary ACTH Hypersecretion

A disease of the PITUITARY GLAND characterized by the excess amount of ADRENOCORTICOTROPIC HORMONE secreted. This leads to hypersecretion of cortisol (HYDROCORTISONE) by the ADRENAL GLANDS resulting in CUSHING SYNDROME.
Also Known As:
Adrenocorticotropic Hormone, Inappropriate Secretion; ACTH Hypersecretion, Pituitary; Disease, Cushing; Hypersecretion, Pituitary ACTH; Cushing Disease; Inappropriate ACTH Secretion Syndrome; Inappropriate Adrenocorticotropic Hormone Secretion
Networked: 281 relevant articles (34 outcomes, 21 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Cushing Syndrome
2. Adenoma (Adenomas)
3. Neoplasms (Cancer)
4. Pituitary Neoplasms (Pituitary Adenoma)
5. Acromegaly

Experts

1. Stratakis, Constantine A: 6 articles (07/2015 - 09/2005)
2. Hamrahian, Amir H: 4 articles (10/2015 - 01/2011)
3. Melmed, Shlomo: 4 articles (07/2015 - 11/2002)
4. Swearingen, Brooke: 4 articles (10/2012 - 05/2011)
5. Weil, Robert J: 3 articles (10/2015 - 01/2011)
6. Ben-Shlomo, Anat: 3 articles (07/2015 - 05/2011)
7. Shah, Nalini S: 3 articles (02/2015 - 11/2010)
8. Yamada, Shozo: 3 articles (04/2014 - 01/2002)
9. Lodish, Maya B: 3 articles (04/2014 - 06/2009)
10. Sinaii, Ninet: 3 articles (04/2014 - 06/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pituitary ACTH Hypersecretion:
1. Adrenocorticotropic Hormone (ACTH)FDA Link
2. Hydrocortisone (Cortisol)FDA LinkGeneric
3. HormonesIBA
4. cabergolineFDA LinkGeneric
5. Dexamethasone (Maxidex)FDA LinkGeneric
6. Protons (Proton)IBA
7. ProlactinIBA
03/01/2015 - "This article discusses some of the recent studies reporting outcomes from endoscopic series for Cushing disease, acromegaly, prolactin-secreting tumors, and nonfunctioning macroadenomas. "
02/01/2003 - "At a median follow-up period of 16 months (range 3-45 months), surgical remission rates were as follows: in 40 patients with endocrine-inactive macroadenomas, 95% for noninvasive and 40% for invasive tumors; in the 20 patients with prolactinomas, 75% for prolactinomas with an initial prolactin (PRL) level lower than 200 ng/ml, 33% for those with a PRL level between 200 and 600 ng/ml, and 0% for those with a PRL level higher than 1400 ng/ml; in the 15 patients with Cushing disease, 73% for microadenomas and 25% for macroadenomas; in the 10 patients with acromegaly, 75% for microadenomas and 50% for macroadenomas; in the five patients with Rathke cleft cysts, 80%; and in the five patients with craniopharyngiomas, 40%. "
01/01/2011 - "Measurement of prolactin during IPSS testing may reduce false-negative results in patients with Cushing disease who do not demonstrate an appropriate central-to-peripheral ACTH gradient. "
03/01/1991 - "[The gonadotropin, prolactin and sex steroid content of the blood from the inferior cavernous sinuses and the adrenal and ovarian veins of women with Itsenko-Cushing disease]."
07/01/1984 - "[Interrelation of disorders in gonadotropin and prolactin secretion and the activity of the hypothalamo-hypophyseal-adrenal system in Itsenko-Cushing disease]."
8. Cyproheptadine (Periactin)FDA Link
9. Bromocriptine (Parlodel)FDA LinkGeneric
10. alpha-TocopherolFDA Link

Therapies and Procedures

1. Adrenalectomy
2. Radiotherapy
3. Aftercare (After-Treatment)
4. Hormone Replacement Therapy (Therapy, Hormone Replacement)
5. Combined Modality Therapy